<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562185</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574034</org_study_id>
    <secondary_id>SCCC-04E07</secondary_id>
    <secondary_id>SCCC-062007-043</secondary_id>
    <secondary_id>ORTHO-SCCC-04E07</secondary_id>
    <nct_id>NCT00562185</nct_id>
  </id_info>
  <brief_title>Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase I/II Study of Intravenous Doxil and Intraperitoneal Carboplatin as Salvage Therapy in Patients With Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech Clinical Affairs, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving doxorubicin together with carboplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I and phase II trial is studying the side effects and best dose of&#xD;
      carboplatin when given together with doxorubicin to see how well it works in treating&#xD;
      patients with recurrent ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose and safety of intravenous doxorubicin&#xD;
           hydrochloride and intraperitoneal carboplatin in patients with platinum-sensitive&#xD;
           recurrent ovarian cancer.&#xD;
&#xD;
        -  To evaluate the feasibility of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the response rate and progression-free survival of patients with recurrent&#xD;
           ovarian cancer who have had no more than two prior salvage regimens.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study of carboplatin followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive doxorubicin hydrochloride IV over 1 hour followed by&#xD;
           carboplatin intraperitoneally on day 1 until the maximum tolerated dose is achieved.&#xD;
           Treatment repeats every 28 days for 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive doxorubicin hydrochloride as in phase I and carboplatin at&#xD;
           the maximum tolerated dose as in phase I.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 4 weeks for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 61 patients (18 patients in phase I and 43 patients in phase&#xD;
      II) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding source withdrew funding&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of intraperitoneal carboplatin when given in combination with IV doxorubicin hydrochloride (phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy and safety (phase II)</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian carcinoma&#xD;
&#xD;
               -  Recurrent disease&#xD;
&#xD;
          -  Known platinum-sensitive recurrent disease after no more than 2 prior salvage regimens&#xD;
&#xD;
          -  Measurable disease as defined by a target lesion and a CA125 level&#xD;
&#xD;
          -  No epithelial ovarian carcinoma of low malignant potential&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  GOG performance status 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/uL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/uL&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and alkaline phosphatase ≤ 3 x ULN&#xD;
&#xD;
          -  Neuropathy (sensory and motor) ≤ CTCAE grade 1&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  GOG performance status 3 or 4&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  History of hypersensitivity reactions attributed to a conventional formulation of&#xD;
             doxorubicin hydrochloride or the components of DOXIL®&#xD;
&#xD;
          -  Abnormal LVEF as determined by gated cardiac radionucleotide scan (MUGA)&#xD;
&#xD;
          -  Septicemia or severe infection&#xD;
&#xD;
          -  Acute hepatitis or severe gastrointestinal bleeding&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  NYHA class II-IV heart failure&#xD;
&#xD;
               -  Uncontrolled angina&#xD;
&#xD;
               -  Severe uncontrolled ventricular arrhythmias&#xD;
&#xD;
               -  Clinically significant pericardial disease&#xD;
&#xD;
               -  Electrocardiographic evidence of acute ischemic or active conduction system&#xD;
                  abnormalities&#xD;
&#xD;
                    -  Patients with evidence of abnormal cardiac conduction (e.g., bundle branch&#xD;
                       block or heart block) are eligible if their disease has been stable for the&#xD;
                       past six months&#xD;
&#xD;
          -  Other invasive malignancies within the past 5 years except for nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior adjuvant regimen&#xD;
&#xD;
          -  At least 4 weeks since prior salvage treatment&#xD;
&#xD;
          -  May have received secondary cytoreduction for recurrent ovarian cancer&#xD;
&#xD;
          -  May have received prior intraperitoneal therapy for ovarian cancer&#xD;
&#xD;
          -  May have received no more than 2 prior platinum and taxane-based regimens&#xD;
&#xD;
          -  May have received prior intraperitoneal platinum during front-line treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior anthracycline dose exceeding 360 mg/m^2 for doxorubicin hydrochloride (including&#xD;
             DOXIL®) or 720 mg/m^2 for epirubicin hydrochloride&#xD;
&#xD;
          -  Prior radiotherapy&#xD;
&#xD;
          -  Prior intraperitoneal carboplatin or cisplatin as salvage treatment for recurrent&#xD;
             ovarian cancer&#xD;
&#xD;
          -  Concurrent amifostine or other protective agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayanthi S. Lea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

